以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 在全球慢性疾病负担日益加重的今天，2型糖尿病已成为威胁人类健康的重大公共卫生问题。最新统计数据显示，全球糖尿病患者总数 已突破4.15亿，其中90%为2型糖尿病，每年导致超过400万人死亡。这种可预防却难以治愈的代谢性疾病，不仅显著增加心血管疾 病、痴呆和癌症的发病风险，更给全球医疗体系带来沉重的经济负担。值得关注的是，发表在《Nutriti on & Di a be t e s》期刊上的突破 性研究为糖尿病预防带来了令人振奋的消息——来自英国生物银行（UK Bi oba nk）历时12年、追踪5 0万人的大规模队列研究首次证 实，日常饮食中增加黄酮类物质的摄入可显著降低2型糖尿病发病风险。 这项具有里程碑意义的研究发现，富含黄酮类化合物的天然食物在糖尿病预防中扮演着关键角色。作为植物性食物中特有的多酚类活性 物质，黄酮类化合物广泛存在于茶叶、苹果、浆果、黑巧克力以及红酒等日常饮食中。研究人员通过长期追踪观察发现，保持较高黄酮 类食物摄入习惯 ...

Core Viewpoint - A groundbreaking study conducted by Xi'an Jiaotong University and Harvard University provides authoritative guidance on beverage choices for diabetes patients, revealing significant differences in health impacts among various drinks [6][9]. Group 1: Research Overview - The study tracked 15,486 type 2 diabetes patients over 38 years, utilizing validated food frequency questionnaires to assess beverage intake and its correlation with all-cause mortality and cardiovascular outcomes [6][12]. - The research highlights the urgent need for dietary interventions in diabetes management, given the rising global diabetes prevalence, projected to reach 783 million by 2045 [9]. Group 2: Key Findings - High intake of sugar-sweetened beverages (SSBs) is significantly associated with increased all-cause mortality and adverse cardiovascular outcomes, while coffee, tea, plain water, and low-fat milk show protective effects [6][10]. - Specifically, the highest consumption group of SSBs had a 20% higher risk of all-cause mortality compared to the lowest intake group, while coffee drinkers had a 26% lower risk [13]. Group 3: Clinical Implications - The study suggests that reducing SSB intake and increasing consumption of healthier beverages like coffee, tea, or plain water could be a viable strategy for improving long-term outcomes and reducing mortality risk in type 2 diabetes patients [14]. - The findings provide high-quality evidence for personalized dietary guidance, emphasizing the importance of beverage choices in diabetes management [14].

Core Viewpoint - The National Health Commission of China has issued notifications prohibiting the use of two surgical procedures: "cervical deep lymphatic vessel/vein anastomosis" for Alzheimer's disease and "jejunum-ileum anastomosis" for type 2 diabetes treatment, due to concerns over their safety and efficacy [1][4][12]. Group 1: Alzheimer's Disease and Surgical Procedure - The "cervical deep lymphatic vessel/vein anastomosis" (LVA) is deemed to be in the early exploratory stage of clinical research, lacking clear indications and contraindications, as well as high-quality evidence supporting its safety and effectiveness [4][10]. - The procedure has been evaluated by experts, who concluded that its application in treating Alzheimer's disease is not supported by sufficient clinical evidence, and it poses potential risks that may outweigh benefits for patients with mild symptoms [9][10]. - The National Health Commission has mandated local health authorities to ensure that medical institutions cease the use of LVA for Alzheimer's treatment and to provide follow-up services for affected patients [11]. Group 2: Type 2 Diabetes and Surgical Procedure - The "jejunum-ileum anastomosis" has been evaluated and found to have uncertain safety and effectiveness for treating type 2 diabetes, with potential severe complications such as liver failure and malnutrition [12][14]. - Although some studies suggest that this procedure may improve blood sugar levels post-surgery, the overall clinical evidence remains limited, and it has not been included in the latest diabetes treatment guidelines [13][14]. - The National Health Commission has instructed health authorities to monitor and regulate the clinical application of this procedure, ensuring that institutions stop its use for diabetes treatment and enhance public health education [14].

Core Viewpoint - The article emphasizes the potential of strawberries as a dietary intervention for managing prediabetes and improving metabolic health, supported by clinical research findings that demonstrate significant benefits in blood sugar control and cardiovascular health indicators [4][11][17]. Group 1: Clinical Research Findings - A recent clinical study published in *The Journal of Nutrition* indicates that consuming 2.5 servings of strawberries daily for 12 weeks significantly improves blood glucose metabolism and various cardiovascular metabolic indicators in adults with prediabetes [4][11]. - The study involved a randomized controlled trial design, confirming a causal relationship between strawberry intake and metabolic improvements, rather than mere correlation [4][9]. - Key metabolic improvements observed include an average reduction of 8.9 mg/dl in fasting blood glucose, a 0.2% decrease in glycated hemoglobin, and a 6.9 μIU/ml reduction in serum insulin levels [11]. Group 2: Mechanisms of Action - Strawberries contain various bioactive compounds, such as anthocyanins and ellagic acid, which may enhance insulin sensitivity and reduce chronic inflammation, critical factors in the development of type 2 diabetes [4][13]. - The health benefits of strawberries are attributed to their high polyphenol content, which exhibits antioxidant properties, reduces oxidative stress, and modulates inflammatory pathways [14][15]. - Strawberries also improve lipid metabolism by downregulating key enzymes involved in fat synthesis, leading to favorable changes in cholesterol levels [15]. Group 3: Practical Implications - From a public health perspective, strawberries could provide a palatable and sustainable dietary option for high-risk populations to prevent diabetes [5][17]. - Recommendations suggest a daily intake of approximately 250-300 grams of fresh strawberries for individuals with prediabetes, emphasizing the importance of incorporating them into a balanced diet [16]. - The article highlights the need for further research with larger sample sizes and longer observation periods to establish optimal intake levels and long-term effects of strawberries on metabolic health [5][16].

Core Viewpoint - The overall prevalence of diabetes among adults in China is on the rise, significantly influenced by daily habits such as late dinners, excessive red meat consumption, and high intake of sugary beverages [1][3][4]. Group 1: Eating Habits - Habit 1: Eating dinner too late increases the risk of type 2 diabetes, with a study indicating that late dinners can lead to a 6.7% decrease in insulin and an 8.3% increase in glucose levels [1]. - Habit 2: High consumption of red meat correlates with a higher risk of type 2 diabetes, with those consuming two or more servings per week at greater risk compared to those who eat less [3]. - Habit 3: Daily intake of sugary beverages raises diabetes risk by 41% for those consuming two or more cups daily, and 11% for those drinking artificially sweetened beverages [4][5]. Group 2: Alcohol Consumption - Habit 4: Regular alcohol consumption, particularly beer, can lead to increased blood sugar levels due to its high glycemic index, which is comparable to that of glucose [7][9]. Group 3: Sleep and Lifestyle - Habit 5: Sleeping with lights on can exacerbate insulin resistance, potentially leading to diabetes [10]. - Habit 6: Insufficient sleep (less than 6 hours) is linked to a higher risk of type 2 diabetes, as it can impair insulin sensitivity [12]. - Habit 7: Prolonged sedentary behavior (over 6 hours daily) increases the risk of diabetes by 26.7% compared to those who sit less than 2 hours [14]. - Habit 8: Lack of regular exercise contributes to obesity and diabetes, with recommendations for a mix of aerobic, resistance, and flexibility training [16][17].

Core Viewpoint - Insulin resistance (IR) is a critical mechanism in the development of type 2 diabetes mellitus (T2DM) and is associated with various metabolic disorders and cardiovascular diseases. Improving IR is essential for diabetes prevention and management [2][23]. Summary by Sections Definition and Metabolic Hazards of Insulin Resistance - Insulin resistance is defined as the inability of insulin to effectively stimulate glucose uptake in peripheral tissues and suppress hepatic glucose output. It is significantly negatively correlated with metabolic health indicators such as triglycerides and blood pressure [2]. - A study involving 1,326 T2DM patients found that for every 1 unit increase in HOMA-IR, the risk of cardiovascular events increased by 56%. Additionally, improving insulin resistance can reduce the risk of myocardial infarction by 42% [4]. Mechanisms of Insulin Resistance - Insulin resistance is primarily driven by energy surplus and includes mechanisms such as: - Adipocyte hypertrophy and overflow leading to elevated free fatty acid (FFA) levels [5]. - Chronic low-grade inflammation due to lipid overload, damaging insulin signaling pathways [6]. - Interference in signaling pathways by FFA and cytokines, particularly affecting GLUT4 transport systems [7]. - Decreased adiponectin levels, which diminishes insulin responsiveness [8]. Multi-Mechanism Action of Semaglutide in Improving Insulin Resistance - Semaglutide, a GLP-1 receptor agonist, improves insulin resistance through several mechanisms: - Appetite suppression and reduced energy intake, as shown in a study with 30 obese adults [9]. - Reduction of fat mass and improvement in lipid metabolism, with clinical studies indicating a 3.5 kg reduction in fat tissue and up to 17% reduction in visceral fat in diabetic patients [10]. - Increased adiponectin levels and suppression of inflammatory factors, demonstrating significant anti-inflammatory effects [11]. - Activation of GLUT-4 expression, enhancing glucose uptake and utilization [12]. - Significant reduction in HOMA-IR, with a 1.35% decrease in the GLP-1RA treatment group compared to an increase in the control group [13]. Inclusion of Semaglutide in Guidelines and Consensus - Semaglutide is recommended in various expert consensus documents for its ability to significantly improve insulin resistance, particularly in elderly diabetic patients [14]. - Additional recommendations highlight its use in cold climates where insulin resistance may be exacerbated [16]. - The ADA guidelines also list GLP-1RA as a preferred treatment for overweight/obese diabetic patients [18]. Clinical Treatment Recommendations and Individualized Management - Treatment strategies to improve insulin resistance include prioritizing GLP-1RA and SGLT2 inhibitors for their dual benefits on heart and kidney protection [19]. - Nutritional and exercise interventions are advised to control caloric intake and enhance muscle mass [20]. - Risk management for medications like insulin or thiazolidinediones is crucial to avoid complications [21]. - A multidimensional assessment of insulin resistance should be conducted using HOMA-IR, biochemical indicators, BMI, and waist-to-hip ratio [22]. Conclusion - Insulin resistance is a core pathological mechanism in T2DM and various metabolic disorders. Semaglutide, as a representative GLP-1RA, significantly improves insulin resistance through multiple pathways, making it a vital treatment option for T2DM patients, especially those with obesity and cardiovascular risks [23].

Core Viewpoint - The article highlights significant research contributions from Chinese scholars published in the prestigious journal Cell, focusing on advancements in AI-driven protein activation, nuclear stress bodies' role in inflammation regulation, and a novel bile acid's impact on glucose homeostasis [2][4][15]. Group 1: AI-Driven Protein Activation - A research team from Peking University developed a machine-learning-assisted platform called CAGE-Prox vivo for precise protein activation in living mice, enabling real-time biological studies and therapeutic interventions [4][7]. - The platform allows for the temporary blocking of target protein functions and can be triggered by small molecules, facilitating specific control over protein-protein interactions [7]. Group 2: Nuclear Stress Bodies and Inflammation - A study by the Chinese Academy of Sciences explored the assembly and function of nuclear stress bodies (nSB) under stress conditions, revealing their role in enhancing the transcription of NFIL3, which suppresses inflammatory responses [8][9]. - The research indicates that the expression of NFIL3 is positively correlated with the survival rates of sepsis patients, suggesting a potential therapeutic target for precise diagnosis and treatment of sepsis [12][13]. Group 3: Microbial Bile Acids and Glucose Homeostasis - A collaborative study identified a novel bile acid receptor, MRGPRE, activated by a microbial amino-acid-conjugated bile acid, tryptophan-cholic acid (Trp-CA), which improves glucose regulation [15][18]. - The findings reveal a new mechanism for GLP-1 secretion regulation via MRGPRE, providing insights for developing new diabetes medications without the side effects associated with traditional bile acids [18].

Core Viewpoint - A large-scale study published in JAMA Internal Medicine suggests that certain diabetes medications may reduce the risk of acute exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D) and active COPD [2][6]. Research Overview - The study analyzed data from three major insurance claims databases in the U.S. from 2013 to 2023, using a propensity score-matched cohort design to compare the risk of COPD exacerbations among patients aged 40 and older receiving SGLT-2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors [3][4]. Key Findings - Among 393,847 patients, the matched cohorts included 27,991 pairs for SGLT-2i vs. DPP-4i, 32,107 pairs for GLP-1RA vs. DPP-4i, and 36,218 pairs for SGLT-2i vs. GLP-1RA. The median follow-up period was 145 days, revealing: - SGLT-2i showed a lower risk of COPD exacerbation compared to DPP-4i (9.26 vs. 11.4 per 100 person-years; HR: 0.81; IRD: -2.20) [4]. - GLP-1RAs also demonstrated a lower risk compared to DPP-4is (9.89 vs. 11.49 per 100 person-years; HR: 0.86; IRD: -1.60) [4]. - The difference in acute exacerbation risk between SGLT-2is and GLP-1RAs was minimal (9.47 vs. 10.00 per 100 person-years; HR: 0.94; IRD: -0.55) [5]. Clinical Significance - The findings indicate that SGLT-2is and GLP-1RAs may be superior to DPP-4is for patients with both T2D and COPD, potentially guiding future treatment decisions for this population. The study highlights the potential benefits of these medications beyond glycemic control, particularly for patients managing both conditions [6][8]. Limitations - The study is observational in nature and may have residual confounding factors. Further randomized controlled trials are needed to confirm these findings and explore the mechanisms by which these medications reduce the risk of COPD exacerbations [7].

Core Viewpoint - The study highlights the potential of marine n-3 polyunsaturated fatty acids as a dietary intervention to improve sleep health in type 2 diabetes patients [12]. Group 1: Prevalence and Impact of Sleep Disorders - Approximately 537 million adults globally had diabetes in 2021, projected to rise to 783 million by 2045 [2]. - Sleep disorders are common among type 2 diabetes (T2D) patients, affecting 42%-76.8% of them, indicating a need for evidence-based strategies to improve sleep quality [2]. Group 2: Mechanisms of Sleep Regulation - Sleep regulation involves homeostatic pressure, wake-dependent regulation, and circadian rhythms, controlled by the central biological clock located in the suprachiasmatic nucleus (SCN) [5]. - The expression of clock genes in T2D patients is reduced, correlating with insulin resistance and elevated HbA1c levels, which may exacerbate sleep-wake disorders [6]. Group 3: Role of n-3 Polyunsaturated Fatty Acids - Dietary fat intake is closely linked to sleep and circadian rhythm balance, with a negative correlation observed between oily fish consumption and Pittsburgh Sleep Quality Index (PSQI) scores in the general population [6]. - Previous research confirmed that marine n-3 polyunsaturated fatty acids improve glucose and lipid metabolism in diabetic mice [7]. Group 4: Research Study and Findings - A 14-month randomized controlled trial (RCT) was conducted to assess the effects of fish oil supplements on sleep parameters and central biological clock improvement in T2D patients [8]. - The study found a significant association between regular fish oil intake and improved sleep quality among 27,549 T2D patients [9]. - Fish oil supplements were shown to enhance the expression of central clock genes, including Clock, Bmal1, and Per2, and restore rhythmic oscillation in key biological clock genes in hypothalamic neurons [9][10]. Group 5: Conclusion - The research underscores the potential of marine n-3 polyunsaturated fatty acids as a dietary intervention to enhance sleep health in type 2 diabetes patients [12].

Core Viewpoint - The article discusses the benefits and mechanisms of GLP-1 receptor agonists, particularly focusing on their role in managing type 2 diabetes and supporting weight loss, highlighting their safety and potential cardiovascular benefits [1][3][5]. Summary by Sections GLP-1 Drug Mechanism - GLP-1 receptor agonists mimic the natural hormone GLP-1, which is released from the intestines after eating, enhancing insulin release, reducing appetite, and slowing gastric emptying [3]. - These drugs are administered via injection and are crucial for maintaining stable blood sugar levels in type 2 diabetes patients, thereby preventing long-term complications like cardiovascular diseases and kidney issues [3]. - Unlike insulin, GLP-1 drugs only lower blood sugar when levels are elevated, reducing the risk of hypoglycemia [3]. Weight Loss Support - GLP-1 receptor agonists are gaining attention for their weight loss effects, helping to suppress hunger and reduce calorie intake by delaying gastric emptying [5]. - When used specifically for weight loss, higher doses are typically administered compared to those used for diabetes treatment [5]. - Clinical trials indicate that users can lose 10% to 15% of their body weight within a year, with some achieving over 20% weight loss, significantly improving metabolic health and reducing risks of related diseases [5]. Emerging Benefits and Ongoing Research - Research is ongoing to explore the broader potential of GLP-1 drugs beyond diabetes management and weight loss, including: - Cardiovascular health: Some trials suggest reduced risks of heart attacks and strokes in obese or diabetic patients [6]. - Neuroprotection: Investigations into the role of GLP-1 in slowing cognitive decline and preventing Alzheimer's disease [6]. - Addiction treatment: Preliminary studies indicate potential benefits in reducing cravings for substances like nicotine and alcohol [6]. - Liver health: GLP-1 may help control metabolic liver diseases by reducing liver fat and inflammation [6]. - Sleep apnea: FDA approval for tirzepatide (Zepbound) for treating moderate to severe obstructive sleep apnea in obese adults is expected in December 2024 [6]. Common Side Effects - GLP-1 drugs may cause side effects, particularly gastrointestinal issues like nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which often diminish as the body adjusts [7]. - Other less common reactions include dizziness, fatigue, increased heart rate, headaches, and mild irritation at injection sites [7]. - Continuous nausea or vomiting can lead to dehydration, malnutrition, or kidney problems, and these drugs are not suitable for individuals with severe digestive diseases or during pregnancy and breastfeeding [7][8]. Additional Health Concerns - Potential health issues associated with GLP-1 drugs include a small risk of pancreatitis, gallbladder problems, thyroid tumors (though no clear evidence in humans), and muscle loss due to rapid weight loss, particularly in older adults [8]. - Individuals considering GLP-1 treatment should discuss these risks with healthcare providers and may benefit from strategies to prevent muscle loss [8].